KR102410076B1 - Ror 감마의 조절제로서의 화합물 - Google Patents

Ror 감마의 조절제로서의 화합물 Download PDF

Info

Publication number
KR102410076B1
KR102410076B1 KR1020207010364A KR20207010364A KR102410076B1 KR 102410076 B1 KR102410076 B1 KR 102410076B1 KR 1020207010364 A KR1020207010364 A KR 1020207010364A KR 20207010364 A KR20207010364 A KR 20207010364A KR 102410076 B1 KR102410076 B1 KR 102410076B1
Authority
KR
South Korea
Prior art keywords
cycloalkyl
alkyl
mmol
compound
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207010364A
Other languages
English (en)
Korean (ko)
Other versions
KR20200040917A (ko
Inventor
요한나 바코니
스티븐 리차드 브루넷
델펀 콜린
로버트 오웬 휴즈
샹 리
솽 량
로버트 시블리
마이클 로버트 터너
리펜 우
창 장
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Publication of KR20200040917A publication Critical patent/KR20200040917A/ko
Application granted granted Critical
Publication of KR102410076B1 publication Critical patent/KR102410076B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y10S514/825—
    • Y10S514/863—

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020207010364A 2014-04-14 2015-04-10 Ror 감마의 조절제로서의 화합물 Active KR102410076B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461979231P 2014-04-14 2014-04-14
US61/979,231 2014-04-14
KR1020167031654A KR102410069B1 (ko) 2014-04-14 2015-04-10 Ror 감마의 조절제로서의 화합물
PCT/US2015/025328 WO2015160654A1 (en) 2014-04-14 2015-04-10 Compounds as modulators of ror gamma

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167031654A Division KR102410069B1 (ko) 2014-04-14 2015-04-10 Ror 감마의 조절제로서의 화합물

Publications (2)

Publication Number Publication Date
KR20200040917A KR20200040917A (ko) 2020-04-20
KR102410076B1 true KR102410076B1 (ko) 2022-06-22

Family

ID=52998264

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207010364A Active KR102410076B1 (ko) 2014-04-14 2015-04-10 Ror 감마의 조절제로서의 화합물
KR1020167031654A Active KR102410069B1 (ko) 2014-04-14 2015-04-10 Ror 감마의 조절제로서의 화합물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167031654A Active KR102410069B1 (ko) 2014-04-14 2015-04-10 Ror 감마의 조절제로서의 화합물

Country Status (35)

Country Link
US (5) US9242989B2 (enExample)
EP (2) EP3131902B1 (enExample)
JP (2) JP6282759B2 (enExample)
KR (2) KR102410076B1 (enExample)
CN (3) CN106132965B (enExample)
AP (1) AP2016009403A0 (enExample)
AR (2) AR100058A1 (enExample)
AU (2) AU2015247983B2 (enExample)
BR (2) BR112016021962A2 (enExample)
CA (1) CA2944787C (enExample)
CL (1) CL2016002421A1 (enExample)
CY (1) CY1122012T1 (enExample)
DK (1) DK3131902T3 (enExample)
EA (2) EA031351B1 (enExample)
ES (1) ES2744299T3 (enExample)
HR (1) HRP20191579T1 (enExample)
HU (1) HUE045847T2 (enExample)
IL (2) IL247419B (enExample)
LT (1) LT3131902T (enExample)
MA (1) MA46373A (enExample)
ME (1) ME03513B (enExample)
MX (1) MX370780B (enExample)
MY (1) MY182834A (enExample)
NZ (1) NZ723530A (enExample)
PE (2) PE20161572A1 (enExample)
PH (2) PH12016502019B1 (enExample)
PL (1) PL3131902T3 (enExample)
PT (1) PT3131902T (enExample)
RS (1) RS59170B1 (enExample)
SG (1) SG11201608537SA (enExample)
SI (1) SI3131902T1 (enExample)
TW (2) TWI652268B (enExample)
UA (2) UA120094C2 (enExample)
UY (1) UY36077A (enExample)
WO (1) WO2015160654A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA120094C2 (uk) * 2014-04-14 2019-10-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Сполуки як модулятори ror-гамма
FR3030518B1 (fr) * 2014-12-19 2018-03-23 Galderma Research & Development Derives sulfonamides en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t)
CN108026045B (zh) 2015-05-15 2021-04-27 奥瑞基尼探索技术有限公司 用作RORγ调节剂的经过取代的四氢喹啉酮化合物
WO2017058831A1 (en) * 2015-10-01 2017-04-06 Boehringer Ingelheim International Gmbh Pteridine derivatives as modulators of ror gamma
JP6448867B2 (ja) 2015-12-15 2019-01-09 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ イソインドール化合物
WO2017127375A1 (en) * 2016-01-20 2017-07-27 Boehringer Ingelheim International Gmbh Pyrazinedihydropyrimidinone or pyridazinedihydropyrimidinone compounds as modulators of ror gamma
TWI705958B (zh) 2016-12-05 2020-10-01 荷蘭商領導醫藥控股責任有限公司 ＲＯＲγ調節子
US20200031753A1 (en) 2017-04-06 2020-01-30 Boehringer Ingelheim International Gmbh Cyclopropyl alkyl amines and process for their preparation
WO2018229155A1 (en) 2017-06-14 2018-12-20 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
CN109206346A (zh) * 2017-07-01 2019-01-15 复旦大学 叔胺类衍生物或其盐及其制备方法和用途
CN107903263B (zh) * 2017-12-28 2019-11-12 山东铂源药业有限公司 一种帕布昔利布中间体的合成方法
MY208400A (en) 2018-05-03 2025-05-07 Shanghai hengrui pharmaceutical co ltd Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ror) and pharmaceutical uses thereof
JP2022504780A (ja) 2018-10-18 2022-01-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 光学活性１－シクロプロピルアルキル－１－アミンのスケーラブルな合成
US20230014730A1 (en) 2019-09-23 2023-01-19 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
TW202118751A (zh) 2019-10-31 2021-05-16 大陸商江蘇恒瑞醫藥股份有限公司 RORγ調節劑的酸加成鹽
WO2022106547A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Process for synthesising a ror gamma inhibitor
WO2022106551A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Co-crystals of a ror gamma inhibitor
WO2022106548A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Solid forms of a ror gamma inhibitor
WO2022106550A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Crystalline polymorphic form of a ror gamma inhibitor
WO2022106549A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Crystalline salts of a ror gamma inhibitor
WO2023216910A1 (zh) * 2022-05-07 2023-11-16 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为usp1抑制剂
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19
CN116178279A (zh) * 2023-03-15 2023-05-30 上海药坦药物研究开发有限公司 一种5-溴-4-环丙基-6-甲氧基嘧啶及其中间体的制备方法
WO2024229569A1 (en) * 2023-05-09 2024-11-14 11949098 Canada Inc. Inverse agonists of rar related orphan receptors (rors)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024966A1 (en) 2001-08-14 2003-03-27 Astrazeneca Ab Pteridinone derivatives as modulators of chemokine receptor activity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009022185A2 (en) * 2007-08-16 2009-02-19 Astrazeneca Ab 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use
AP2739A (en) 2008-09-26 2013-09-30 Boehringer Ingelheim Int Azaindazole compounds as CCRI receptor antagonists
PL2491028T3 (pl) 2009-10-21 2014-05-30 Boehringer Ingelheim Int Związki indazolowe i pirazolopirydynowe jako antagoniści receptora CCR1
WO2012167046A1 (en) * 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
US9670213B2 (en) * 2012-05-14 2017-06-06 East China University Of Science And Technology Pteridine ketone derivative and applications thereof as EGFR, BLK, and FLT3 inhibitor
UA120094C2 (uk) * 2014-04-14 2019-10-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Сполуки як модулятори ror-гамма
WO2017058831A1 (en) * 2015-10-01 2017-04-06 Boehringer Ingelheim International Gmbh Pteridine derivatives as modulators of ror gamma
WO2017127375A1 (en) * 2016-01-20 2017-07-27 Boehringer Ingelheim International Gmbh Pyrazinedihydropyrimidinone or pyridazinedihydropyrimidinone compounds as modulators of ror gamma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024966A1 (en) 2001-08-14 2003-03-27 Astrazeneca Ab Pteridinone derivatives as modulators of chemokine receptor activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 19, 4092-4096 (2009)
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 23(2), 532-536 (2013)

Also Published As

Publication number Publication date
WO2015160654A1 (en) 2015-10-22
PE20161572A1 (es) 2017-02-01
AP2016009403A0 (en) 2016-08-31
US20160075706A1 (en) 2016-03-17
MA46373A (fr) 2019-08-07
EA201890329A1 (ru) 2018-07-31
JP6463855B2 (ja) 2019-02-06
UA121255C2 (uk) 2020-04-27
MX370780B (es) 2020-01-03
EP3418280B1 (en) 2023-07-12
US20190002465A1 (en) 2019-01-03
JP6282759B2 (ja) 2018-02-21
IL247419B (en) 2019-03-31
IL263878A (en) 2019-01-31
US20180022749A1 (en) 2018-01-25
SG11201608537SA (en) 2016-11-29
AU2015247983B2 (en) 2019-05-16
EA035063B1 (ru) 2020-04-23
CY1122012T1 (el) 2020-10-14
AU2019203027B2 (en) 2020-07-09
KR102410069B1 (ko) 2022-06-20
HK1244800A1 (zh) 2018-08-17
AR100058A1 (es) 2016-09-07
US20150291607A1 (en) 2015-10-15
DK3131902T3 (da) 2019-09-02
HRP20191579T1 (hr) 2019-11-29
CN107266450A (zh) 2017-10-20
NZ723530A (en) 2023-05-26
UA120094C2 (uk) 2019-10-10
RS59170B1 (sr) 2019-10-31
IL263878B (en) 2019-11-28
EP3131902B1 (en) 2019-06-12
JP2017511357A (ja) 2017-04-20
LT3131902T (lt) 2019-09-25
CA2944787A1 (en) 2015-10-22
EA201691978A1 (ru) 2017-02-28
BR112016021962B1 (pt) 2022-12-13
US9598415B2 (en) 2017-03-21
HK1244801A1 (zh) 2018-08-17
CA2944787C (en) 2023-03-14
PH12016502019B1 (en) 2020-10-23
US20170008894A1 (en) 2017-01-12
AU2019203027A1 (en) 2019-05-23
AU2015247983A1 (en) 2016-09-08
CN107266454A (zh) 2017-10-20
TW201841915A (zh) 2018-12-01
EP3418280A1 (en) 2018-12-26
PH12016502019A1 (en) 2017-01-09
TWI655192B (zh) 2019-04-01
CN107266454B (zh) 2019-08-09
CL2016002421A1 (es) 2017-03-24
EA031351B1 (ru) 2018-12-28
MX2016013342A (es) 2017-01-26
PT3131902T (pt) 2019-09-17
EP3131902A1 (en) 2017-02-22
BR112016021962A2 (pt) 2023-01-20
ES2744299T3 (es) 2020-02-24
PH12020500252A1 (en) 2021-07-26
US9242989B2 (en) 2016-01-26
PE20211002A1 (es) 2021-06-01
TW201625622A (zh) 2016-07-16
JP2018065874A (ja) 2018-04-26
AR119454A2 (es) 2021-12-22
SI3131902T1 (sl) 2019-10-30
MY182834A (en) 2021-02-05
PL3131902T3 (pl) 2019-11-29
CN106132965A (zh) 2016-11-16
KR20200040917A (ko) 2020-04-20
CN106132965B (zh) 2020-02-07
KR20160142396A (ko) 2016-12-12
UY36077A (es) 2015-10-30
TWI652268B (zh) 2019-03-01
HUE045847T2 (hu) 2020-01-28
ME03513B (me) 2020-04-20
BR122020020657B1 (pt) 2022-12-20
CN107266450B (zh) 2020-07-24

Similar Documents

Publication Publication Date Title
KR102410076B1 (ko) Ror 감마의 조절제로서의 화합물
JP6192836B2 (ja) Ｒｏｒｃモジュレーターとしてのアザインドール化合物
EP3041821B1 (en) Bicylic compounds as modulators of rorgamma
JP2019507120A (ja) ガンマのモジュレータとしての化合物
HK1227037A1 (en) Compounds as modulators of ror gamma
HK1244800B (zh) 作为RORγ调节剂的化合物
HK1227037B (zh) 作为RORγ调节剂的化合物
HK1244801B (zh) 作为RORγ调节剂的化合物
TW201838997A (zh) 作為RORγ調節劑之化合物

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200409

Application number text: 1020167031654

Filing date: 20161111

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200508

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211018

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220404

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220614

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220615

End annual number: 3

Start annual number: 1

PG1601 Publication of registration